



41

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C07K 14/35, C12N 9/02, 15/31, 15/53, 15/63, 5/08, C07K 16/18, A61K 38/08, G01N 33/68		A1	(11) International Publication Number: WO 95/25744 (43) International Publication Date: 28 September 1995 (28.09.95)
(21) International Application Number: PCT/NL95/00108 (22) International Filing Date: 21 March 1995 (21.03.95) (30) Priority Data: 94200721.2 21 March 1994 (21.03.94) EP (34) Countries for which the regional or international application was filed: AT et al. 94200738.6 22 March 1994 (22.03.94) EP (34) Countries for which the regional or international application was filed: AT et al. 94202927.3 10 October 1994 (10.10.94) EP (34) Countries for which the regional or international application was filed: AT et al. (71) Applicant (for all designated States except US): RIJKSUNI- VERSITEIT UTRECHT [NL/NL]; Heidelberglaan 8, NL- 3584 CS Utrecht (NL). (72) Inventors; and (75) Inventors/Applicants (for US only): ANDERTON, Stephen, Mark [GB/GB]; 28 St. Stephen's Place, Westfield Lane, Cambridge CB3 0JE (GB). VAN DER ZEE, Ruurd [NL/NL]; Zandhofsestraat 25, NL-3572 CA Utrecht (NL).		(74) Agents: DE BRUIJN, Leendert, C. et al.; Nederlandsch Octrooibureau, Scheveningseweg 82, P.O. Box 29720, NL- 2502 LS The Hague (NL). (81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published With international search report.	
(54) Title: PEPTIDE FRAGMENTS OF MICROBIAL STRESS PROTEINS AND PHARMACEUTICAL COMPOSITION MADE THEREOF FOR THE TREATMENT AND PREVENTION OF INFLAMMATORY DISEASES			
(57) Abstract <p>Peptides are provided which are useful for protection against or treatment of an inflammatory disease, including autoimmune diseases, such as diabetes, arthritic diseases, atherosclerosis, multiple sclerosis, myasthenia gravis, or inflammatory responses due to tumour or transplant rejection. The peptides contain a part of the aminoacid sequence of a microbial protein having a conserved mammalian stress protein homologue, wherein the overall aminoacid sequence identity between the microbial and the mammalian homologues is at least 25 %, and the sequence identity between the microbial and the mammalian homologues of an area of at least 75 consecutive aminoacids is at least 30 %, said part comprising at least 5 aminoacids which are in the same relative position as the same aminoacids in a T cell epitope of said stress protein, which epitope contains at least 4 consecutive aminoacids which are identical with the corresponding mammalian stress protein aminoacids. Nucleotide sequences, expression systems, antibodies and pharmaceutical and diagnostic compositions derived from these peptides are provided as well.</p>			